Benefits
Acute ischemic stroke (2024 meta-analysis)
A meta-analysis found that lumbrokinase improved neurological function and reduced laboratory markers of thrombosis in acute ischemic stroke alongside supportive care. Important framing: this is adjunctive evidence, not a replacement for alteplase or other established stroke therapy, and the included trials were predominantly Chinese with acknowledged methodological limitations.
Secondary ischemic stroke prevention
Multicenter randomized parallel-group controlled trial evidence supports secondary ischemic stroke prevention via an oral fibrinogen-depleting agent. Should be discussed with a neurologist before use in any patient with prior stroke given the bleeding-risk profile of fibrinolytic agents.
Cerebral infarct hemostasis modulation (Jin et al.)
In cerebral infarct subjects given lumbrokinase 3 x 400 mg/day for 28 days, KPTT was prolonged, tPA activity and D-dimer increased, and fibrinogen decreased significantly. Mechanistic confirmation that oral lumbrokinase produces measurable changes in hemostasis parameters.
Diabetic foot ulcer healing (Rey et al.)
In diabetic foot ulcer subjects given lumbrokinase 3 x 500 mg/day for 7 days, fibrinolytic activity improvements were observed. Small emerging application; sample size and duration limit conclusions.
DLBS1033 hemostasis healthy volunteers
DLBS1033, the Indonesian commercial form, showed in a healthy-volunteer hemostasis trial fibrinogenolytic activities on fibrinogen α/β/γ chains, decreased platelet aggregation, and prolonged clotting time. Adds non-Chinese geographic generalizability to the lumbrokinase evidence base.
DLBS1033 acute ischemic stroke RCT
DLBS1033 add-on therapy was studied in acute ischemic stroke in Indonesia. Indonesian/Western evidence supplementing the predominantly Chinese trial base.
Preclinical cardioprotection
Preclinical models show Sirt1 activation with post-ischemic cardioprotection and TLR4 signaling inhibition with cardioprotective effects. Preclinical mechanistic findings, not yet translated to clinical cardiovascular endpoints.
Mechanism of action
Direct fibrinolysis (fibrin-specific)
Lumbrokinase directly degrades fibrin with specificity that exceeds nattokinase's broader proteolytic activity. The fibrin-specificity is the distinguishing pharmacological feature — favorable for the bleeding-risk profile compared to non-specific systemic fibrinolytics.
Indirect fibrinolysis via tPA / plasminogen activation
Lumbrokinase enhances endogenous fibrinolysis by promoting tissue plasminogen activator (tPA) activity and plasminogen-to-plasmin conversion. Indirect mechanism amplifying the body's own fibrinolytic system.
Six-enzyme group (Cho 2004 + Mihara 1991 characterization)
Foundational characterization work purified and characterized six fibrinolytic serine proteases - abundant asparagine/aspartic acid and minimal proline/lysine, distinguishing the compositional profile from typical serine proteases.
Higher thermal stability and alkali resistance
Lumbrokinase shows higher thermal and alkali stability than urokinase, streptokinase, or tPA — the property that makes oral administration viable. Without these stability features, the enzyme would be destroyed by gastric processing before reaching circulation.
Does not directly convert plasminogen to plasmin
Unlike streptokinase or urokinase, lumbrokinase does not directly activate systemic plasminogen. This contributes to the lower bleeding-risk profile vs systemic fibrinolytics — though the safety advantage is relative, not absolute.
TLR4 signaling inhibition (preclinical)
Preclinical evidence that lumbrokinase inhibits TLR4 signaling, contributing to anti-inflammatory and cardioprotective effects in animal models. Mechanistic rationale that has not yet been confirmed in clinical trials.
Sirt1 activation (preclinical)
Preclinical evidence of Sirt1 pathway activation contributing to post-ischemic cardioprotection. Animal-model finding pending human translation.
Clinical trials
2024 pooled analysis following PRISMA guidelines with grade evidence quality assessment and RoB 2.0 risk-of-bias evaluation.
Clinical population described in trial publication.
2024 pooled analysis following PRISMA guidelines with grade evidence quality assessment and RoB 2.0 risk-of-bias evaluation. Lumbrokinase improved neurological function and reduced laboratory thrombosis markers in acute ischemic stroke alongside supportive care. The most rigorous evidence summary for the ingredient — but included trials are predominantly Chinese with methodological limitations.
Clinical evidence on Lumbrokinase (Earthworm Fibrinolytic Enzyme) for the indications and outcomes described.
Clinical population described in trial publication.
Cao YJ et al. 2013, Chin Med J 126:4060-4065. Multicenter randomized parallel-group controlled clinical trial for secondary ischemic stroke prevention via oral fibrinogen-depleting agent. Foundational Chinese multicenter evidence; methodological limitations acknowledged in subsequent pooled analyses.
Clinical evidence on Lumbrokinase (Earthworm Fibrinolytic Enzyme) for the indications and outcomes described.
Clinical population described in trial publication.
Jin et al. — 51 cerebral infarct subjects, lumbrokinase 3 × 400 mg/day for 28 days. KPTT prolonged, tPA activity and D-dimer increased, fibrinogen decreased significantly. Mechanistic confirmation of oral lumbrokinase effects on hemostasis parameters.